Intrinsic Therapeutics, which developed the Barricaid spine procedure, named Keith Valentine as president and CEO.
Mr. Valentine will also join the board of directors and begin his role in early May, according to an April 10 news release. He previously worked at Medtronic, NuVasive, SeaSpine and Orthofix.
“Keith has a demonstrated track record of generating outstanding growth commercializing innovative spinal implants in his previous senior roles at NuVasive and SeaSpine,” Ryan Drant, chair of Intrinsic Therapeutics’ board, said in the release. “With Barricaid’s CPT-1 code becoming effective in January 2026, Keith brings the right combination of energy, leadership skills and spine industry experience to maximize the Barricaid opportunity and help hundreds of thousands of patients annually avoid unnecessary disc reherniations and related surgeries.”
